HKSE · 7630.HK · HKD
Stock price, earnings
Quote as of Oct 30, 2026, 05:04 AM UTC. Cached market data; not a live quote.
One-year closing-price history · HKD. Historical prices are not a forecast.
Impact Therap-b’s quoted price sits in the lower half of its reported 52-week range, 80.76% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Impact Therap-b’s next earnings report is currently expected on Mar 3, 2027, with estimated earnings per share of -HK$0.33. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Impact Therap-b’s reporting calendar.
THE COMPANY BEHIND THE TICKER
IMPACT Therapeutics, a biotechnology firm, specializes in the discovery and advancement of precision anti-cancer treatments rooted in synthetic lethality, operating across China and international markets. The company's primary offering, Senaparib (IMP4297), is a PARP1/2 inhibitor currently deployed as a first-line maintenance therapy for ovarian cancer. Beyond this, Impact Therapeutics maintains a robust pipeline of investigational drugs. This includes IMP1734, a next-generation PARP1 selective inhibitor undergoing Phase I/II trials as a standalone treatment for advanced solid tumors. Another promising candidate is IMP9064, an ATR kinase selective inhibitor, also in Phase I/II clinical studies for advanced solid tumors as a monotherapy. IMP1707, a PARP1 selective inhibitor capable of penetrating the central nervous system, is in Phase I development for homologous recombination repair-deficient tumors. Additionally, IMP7068, an advanced WEE1 inhibitor, is progressing through Phase I/II clinical trials for various advanced solid tumors. Furthermore, a range of other compounds, namely IMP22, IMP25, IMP08, IMP13, IMP10, IMP27, and IMP32, are in the preclinical development phase. The company, established in 2009, is headquartered in Shanghai, China.
Latest available per-share figures in HKD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:19 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
KEEP COMPARING
HK$437.80HK$0.00 (0.0%)
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 22.17% below the high.
HK$17.70+HK$0.02 (+0.11%)
Zai Lab Limited’s quoted price sits in the upper half of its reported 52-week range, 17.37% below the high.
HK$11.66-HK$0.01 (-0.09%)
InnoCare Pharma Limited’s quoted price sits in the lower half of its reported 52-week range, 28.02% below the high.
HK$24.22-HK$0.74 (-2.96%)
GenFleet Therapeutics (Shanghai) Inc.’s quoted price sits in the lower half of its reported 52-week range, 54.22% below the high.
HK$6.34-HK$0.15 (-2.31%)
Alphamab Oncology’s quoted price sits in the lower half of its reported 52-week range, 48.03% below the high.
HK$3.25+HK$0.19 (+6.04%)
Lepu Biopharma Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 52.76% below the high.
HK$6.43+HK$0.09 (+1.34%)
Abbisko Cayman Limited’s quoted price sits in the lower half of its reported 52-week range, 57.42% below the high.
HK$1.58+HK$0.01 (+0.32%)
Edding Genor Group Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 59.49% below the high.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
